LivaNova PLC LIVN R2KR3KPHARMA

Q: What is the current share price of LivaNova PLC (LIVN)?

As of 2026-09-07 16:24 PDT, LivaNova PLC (LIVN) trades at $81.92 on NasdaqGS. Its 52-week range is $49.57 to $85.32.

Q: What is the market capitalisation of LIVN?

LivaNova PLC (LIVN) has a market capitalisation of $4.51B on NasdaqGS.

Q: What is the P/E ratio of LIVN?

LIVN trades at a trailing price-to-earnings (P/E) ratio of 24.17. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 3.45.

Q: What is the return on equity (ROE) of LIVN?

LIVN has a return on equity (ROE) of 15.40%. Its return on capital employed (ROCE) is 11.09%.

Q: Is LIVN a good stock to buy?

This page provides a data-driven analysis of LivaNova PLC (LIVN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Medical Devices · United Kingdom

https://www.livanova.com

Company Profile ↓

$81.92

+54.39% 1Y

Mkt Cap$4.51B

P/E24.17

P/B3.45

52W High$85.32

52W Low$49.57

Book Value$22.06

EPS (TTM)$3.39

Company Overview

LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and depression. This segment also includes the development and clinical testing of aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, hospitals, other healthcare professionals and medical institutions, and healthcare providers. The company sells its medical devices through direct sales representatives, agents, and independent distributors in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. LivaNova PLC was incorporated in 2015 and is headquartered in Gloucester, the United Kingdom.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 15.4%, reflecting efficient use of shareholder capital.

Steady Revenue Expansion

Revenue has grown at a 15.6% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 24.2, below the sector median of 25.2.

Healthy Margins

Operating margin of 15.5% supports profitability.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.27.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $1.39B (+10.7% YoY); net profit $-242.47M.
Trailing 12 Months Year-on-year growth — revenue +10.8%, earnings +287.8%.
5-Year Trend Long-term compounding — revenue CAGR 15.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	15.59%
1 Year:	10.80%

Compounded Profit Growth

5 Years:	-
1 Year:	287.80%

Stock Price Performance

1 Year:	+54.39%
6 Months:	+28.32%
3 Months:	+13.21%
1 Month:	+8.10%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 90% of range

$49.57 $85.32

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)55.88 · Neutral

Price Performance

1M+8.10%

3M+13.21%

6M+28.32%

1Y+54.39%

Valuation vs Sector

P/E of 24.17 is below the sector median of 25.17 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Compounding revenue at 15.6% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

24.17

Industry PE

25.17

Forward P/E

17.50

PEG Ratio

0.93

Book Value

$22.06

Price to Book

3.45

P/S

2.85

EV/EBITDA

15.06

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

15.59%

Profit 5Y

Revenue (YoY)

10.80%

Earnings (YoY)

287.80%

Profitability & Returns

ROCE

11.09%

ROE

15.40%

ROA

5.23%

Profit Margin

12.81%

Op Margin

15.52%

Gross Margin

68.27%

EPS (Latest Qtr)

$1.93

EPS (TTM)

$3.39

Balance Sheet & Liquidity

Debt/Equity

0.27

Quick Ratio

1.08

Current Ratio

1.45

Debt

$351.95M

Total Assets

$2.64B

Current Assets

Working Capital

Ownership

Promoter Holding

0.42%

Chg in Prom Hold

-0.00%

FII / Inst Holding

113.22%

Chg in FII Hold

0.04%

Financial Snapshot

Enterprise Value

$4.51B

Total Revenue (TTM)

$1.47B

EBITDA

$267.84M

Free Cash Flow

$64.69M

Operating Cash Flow

$249.26M

Shares Outstanding

55.09M

Gross Margin

68.27%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	LIVN LivaNova PLC R2KR3KPHARMA	81.92	24.17	$4.51B	0.00%	11.09%	15.40%	15.59%	-
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,149.36	38.57	$1.02T	0.58%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	275.23	31.97	$663.28B	2.09%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	256.46	72.45	$453.19B	2.84%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	150.33	120.26	$371.29B	2.65%	-	34.70%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	397.14	25.54	$356.47B	2.33%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	159.99	24.20	$304.10B	3.03%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	162.70	24.36	$252.33B	1.98%	15.97%	21.96%	9.82%	45.96%
9	AMGN Amgen Inc. NDXSPXR3KPHARMA	437.23	27.14	$235.98B	2.49%	13.95%	91.47%	5.51%	5.55%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Oct 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-	-	-	226.82M	255.84M	251.25M	278.36M	250.40M	287.50M	272.08M	296.98M	250.80M	277.17M	268.61M	287.59M	242.40M	182.21M	240.08M	269.56M	247.60M	264.48M	253.22M	270.06M	240.18M	254.15M	252.60M	263.42M	293.88M	286.11M	294.91M	318.57M	318.12M	316.86M	352.52M	357.75M	362.26M	390.59M
Gross Profit	142.30M	131.73M	148.45M	153.90M	57.98M	125.42M	147.65M	170.10M	161.86M	172.23M	162.09M	193.96M	174.35M	204.07M	163.60M	197.11M	179.41M	204.64M	165.31M	114.97M	147.59M	166.90M	163.41M	172.28M	168.66M	201.64M	168.44M	184.35M	170.92M	174.08M	205.20M	201.80M	203.21M	214.88M	221.03M	216.25M	238.99M	244.85M	243.75M	273.67M
Operating Income	-	-9.07M	25.02M	30.37M	-	-14.88M	19.75M	27.77M	30.02M	18.94M	12.53M	21.61M	-5.76M	-276.45M	-20.78M	-29.88M	25.76M	-143.98M	-581.00K	-16.74M	-7.55M	-249.02M	-5.70M	-36.26M	16.42M	24.75M	9.51M	31.76M	-131.97M	-2.34M	17.38M	4.46M	16.25M	40.17M	35.62M	48.62M	54.18M	54.01M	41.47M	49.48M
Net Income	-16.94M	-40.38M	8.96M	-1.57M	-25.09M	-29.80M	11.27M	47.50M	27.83M	-111.69M	13.27M	15.07M	-7.18M	-210.56M	-14.85M	-29.21M	32.12M	-143.23M	36.46M	-89.42M	-14.81M	-281.05M	-30.76M	-56.49M	-43.44M	-5.13M	2.99M	16.44M	-107.34M	7.37M	1.16M	-7.32M	-41.94M	16.33M	32.95M	-327.32M	27.16M	26.78M	22.29M	108.57M
Diluted EPS	-0.41	-0.83	0.18	-0.03	-0.96	-0.61	0.23	0.98	0.57	-2.32	0.27	0.31	-0.15	-4.34	-0.31	-0.60	0.66	-2.96	0.75	-1.84	-0.30	-5.78	-0.63	-1.15	-0.84	-0.10	0.06	0.30	-2.01	0.14	0.02	-0.14	-0.78	0.30	0.60	-6.01	0.50	0.49	0.40	1.93
R&D Expense	-	31.69M	30.21M	32.17M	-	-	20.39M	33.83M	22.90M	-	31.75M	34.22M	42.42M	-	43.58M	34.54M	45.90M	-	35.90M	25.15M	47.37M	-	44.62M	52.56M	42.13M	-	40.92M	34.23M	35.73M	49.99M	51.12M	46.54M	45.66M	44.74M	48.80M	37.88M	47.19M	48.58M	58.70M	53.66M

Profit & Loss (Annual)

Figures in USD.

Metric	Apr 2014	Apr 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	282.01M	291.56M	964.86M	1.01B	1.11B	1.08B	934.24M	1.04B	1.02B	1.15B	1.25B	1.39B
Gross Profit	254.66M	264.25M	559.51M	651.62M	-	723.80M	594.76M	705.99M	707.23M	755.82M	853.48M	939.87M
Operating Income	80.01M	88.65M	33.45M	96.49M	-248.07M	-171.55M	-273.90M	-784.00K	-76.75M	-68.50M	129.05M	199.39M
Net Income	54.89M	57.85M	-62.79M	-25.09M	-189.40M	-157.64M	-348.82M	-135.82M	-86.25M	17.55M	63.23M	-242.47M
Diluted EPS	2.00	2.17	-1.28	-0.52	-3.91	-3.26	-7.18	-2.68	-1.61	0.32	1.16	-4.45
R&D Expense	45.22M	42.24M	82.08M	109.52M	145.95M	146.85M	152.90M	183.41M	155.81M	193.82M	182.51M	185.76M

Balance Sheet (Annual)

Figures in USD.

Metric	Apr 2013	Apr 2014	Apr 2015	Oct 2015	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	315.94M	-	2.56B	2.34B	2.50B	2.55B	2.41B	2.40B	2.20B	2.29B	2.43B	2.51B	2.61B
Total Equity	229.57M	259.10M	276.57M	74.43M	1.81B	1.71B	1.82B	1.50B	1.38B	1.11B	1.29B	1.21B	1.28B	1.32B	1.20B
Cash & Equivalents	103.30M	124.19M	124.19M	-	112.61M	39.79M	93.61M	47.20M	61.14M	252.83M	207.99M	214.17M	266.50M	428.86M	635.55M
Long Term Debt	-	-	0	-	91.79M	75.22M	61.96M	139.54M	260.33M	642.30M	9.85M	518.07M	568.54M	549.62M	345.19M
Total Liabilities	-	-	39.37M	-	747.28M	635.72M	688.58M	1.05B	1.03B	1.29B	906.31M	1.09B	1.15B	1.19B	1.41B
Current Liabilities	-	-	31.45M	-	359.12M	349.89M	406.02M	496.75M	512.55M	309.05M	696.97M	297.40M	334.98M	392.12M	808.07M

Cash Flows (Annual)

Figures in USD.

Metric	Apr 2014	Apr 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	54.20M	79.68M	90.15M	91.34M	120.49M	-91.14M	-79.42M	102.54M	69.92M	74.91M	183.04M	254.34M
Investing Cash Flow	-34.41M	-9.77M	-44.52M	-52.85M	-120.56M	-41.29M	-41.84M	36.90M	-38.41M	-40.33M	-48.16M	-72.91M
Financing Cash Flow	-37.27M	-48.26M	-118.04M	11.29M	-42.35M	146.58M	310.76M	-181.48M	280.13M	21.48M	18.55M	-285.66M
Capital Expenditure	-15.22M	-6.69M	-38.36M	-32.93M	-37.19M	-24.69M	-35.02M	-25.48M	-26.52M	-34.98M	-47.11M	-81.05M
Free Cash Flow	38.97M	72.99M	51.79M	58.41M	83.30M	-115.83M	-114.45M	77.07M	43.40M	39.93M	135.93M	173.29M
Share Buybacks	72.36M	55.02M	54.49M	0	50.00M	0	0	-	-	-	-	-

Ratios (Annual)

Figures in %.

Metric	Apr 2014	Apr 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	90.3%	90.6%	58.0%	64.4%	-	66.8%	63.7%	68.2%	69.2%	65.5%	68.1%	67.7%
Operating Margin %	28.4%	30.4%	3.5%	9.5%	-22.4%	-15.8%	-29.3%	-0.1%	-7.5%	-5.9%	10.3%	14.4%
Net Margin %	19.5%	19.8%	-6.5%	-2.5%	-17.1%	-14.5%	-37.3%	-13.1%	-8.4%	1.5%	5.0%	-17.5%
ROE %	21.2%	20.9%	-3.7%	-1.4%	-12.6%	-11.4%	-31.4%	-10.5%	-7.1%	1.4%	4.8%	-20.2%
ROCE %	-	31.2%	1.7%	4.6%	-12.1%	-9.0%	-13.1%	-0.1%	-3.8%	-3.3%	6.1%	11.1%

Shareholding Pattern

Insiders

0.42%

Institutions

113.22%

Public Float

113.70%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	13.73%	7.57M	$607.65M
2	Primecap Management Company	7.57%	4.17M	$334.80M
3	FMR, LLC	5.71%	3.15M	$252.77M
4	Hood River Capital Management LLC	4.66%	2.57M	$206.06M
5	AQR Capital Management, LLC	4.28%	2.36M	$189.25M
6	Invesco Ltd.	4.06%	2.24M	$179.70M
7	Artisan Partners Limited Partnership	4.04%	2.22M	$178.69M
8	State Street Corporation	3.93%	2.17M	$173.96M
9	American Century Companies Inc	3.66%	2.01M	$161.75M
10	Dimensional Fund Advisors LP	3.35%	1.85M	$148.21M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for LIVN

Google News hu, 03 Sep 2026

Two New York healthcare talks are set for Sept. 14 and 15, with LivaNova executives taking part. - Stock Titan

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxQOTBkVXJ4OE8wM0x6S2EwMlpOdGMwdTB2MnA5dG1pal9VT0dELThaVngtc2RLRVNHeENsbHNadFdMZkdlYy05OTBIb21SakM1MEpzUEdGWVoyb2xPQTBPeE9MeEtIcGtiOHdveWlsSzFkWVFKdmxIeGVCWHR2aGtZdndRSHpIQ0xqU0hnU2…

Google News Mon, 07 Sep 2026

LivaNova (NASDAQ:LIVN) Combines Growth and Reasonable Valuation - ChartMill

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxPWnA2TlhSYVVRWE9tcWFNTTdUeG9kd2l2by1oMjFJbWlXREh6bUlnVHY1N1ZzQU9WMG1rZ2NRRU9aNm5iWUNPY1F3RmFrb0tnX09FbVlYWDhFSlVod2Fpelp1b3NZenNaSENCcjdaZWphQzB4a3R4a0FQYXJYLUZwYmV5QTY5cXpXeWszQT…

Google News ue, 01 Sep 2026

LivaNova (LIVN) Stock May Be Below Fair Value But Fair On Earnings - simplywall.st

<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxQSkJSdTJ1X010bzdMdzM1eEVocE1haGFyVl92dzhvcVFjNFNraE5GVFRfNXhHVTNjZzRHY1FiNEc1N1k2eEUwdktVX3dVeGpQMlNOWWM4VmVac08zbG5HSTEtbWhucmZ5YXpwc1BjUTZOcFhqb3pLTDhqaDZIemEtUTBJdnFSWmZ2RXppUW…

Google News Fri, 12 Jun 2026

LivaNova (LIVN) Stock Valuation Check After Strong Recent Shareholder Returns - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPWjF3OWZaa0NXN3IxdU04QnVZQ2c1THRrczRrNTFSQUx4YXE4aXlqM1NVMHJkTVB5QVRlVDM1QktiMHZkRUNVNVFhM1FVYjFYa2ZCUThTZEVocExvQnB3N2xsZGpUYXdkZXB5ejZDb3djbkgtOEJ1NmlwUUhZT1VuSFV4WUFtcE1aWXBBSU…

Google News Wed, 05 Aug 2026

$LIVN stock is down 11% today. Here's what we see in our data. - quiverquant.com

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQS01UOC1ISnZfMnhtYVNVWDYtSzFZNkctLTN1ZDBoNmVUYXdCVGNwT3FZRXZRUzJnR2xOTTMyX1JxQ3BtNnZ4NF91S3hySjhRR2NpTlRkMHp1UVZLcXoyMXp3TVYzc2tkLUxUS0RVZWpmc1RRdGhOY3ZKOF8wYTA5QTJfNkdWaFpjR01KOE…

Google News Fri, 04 Sep 2026

LivaNova (NASDAQ: LIVN) executive plans stock sale - Stock Titan

<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxPbnlxRUNWWnpfbmMyLVZmaVg4MVIyVll5SFYzLW5jT2ZDaVRJM2RicHJQYmpiUkJFaUhXRDVNZUc5S0NYbFlzTGxnTTVmLVFRRTNCMURuaHlXT1VERzRJV2hvOS1lMlU5UkNTM2xLMXd0Y19EZDZ1V0g2dWpFaDFtOTcxYTRfUjRfV1FyS1…

LIVN — Frequently Asked Questions

What is the current share price of LivaNova PLC (LIVN)?

As of 2026-09-07 16:24 PDT, LivaNova PLC (LIVN) trades at $81.92 on NasdaqGS. Its 52-week range is $49.57 to $85.32.

What is the market capitalisation of LIVN?

LivaNova PLC (LIVN) has a market capitalisation of $4.51B on NasdaqGS.

What is the P/E ratio of LIVN?

LIVN trades at a trailing price-to-earnings (P/E) ratio of 24.17. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 3.45.

What is the return on equity (ROE) of LIVN?

LIVN has a return on equity (ROE) of 15.40%. Its return on capital employed (ROCE) is 11.09%.

Is LIVN a good stock to buy?

This page provides a data-driven analysis of LivaNova PLC (LIVN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

LivaNova PLC LIVN R2KR3KPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Two New York healthcare talks are set for Sept. 14 and 15, with LivaNova executives taking part. - Stock Titan

LivaNova (NASDAQ:LIVN) Combines Growth and Reasonable Valuation - ChartMill

LivaNova (LIVN) Stock May Be Below Fair Value But Fair On Earnings - simplywall.st

LivaNova (LIVN) Stock Valuation Check After Strong Recent Shareholder Returns - Yahoo Finance

$LIVN stock is down 11% today. Here's what we see in our data. - quiverquant.com

LivaNova (NASDAQ: LIVN) executive plans stock sale - Stock Titan

LIVN — Frequently Asked Questions

What is the current share price of LivaNova PLC (LIVN)?

What is the market capitalisation of LIVN?

What is the P/E ratio of LIVN?

What is the return on equity (ROE) of LIVN?

Is LIVN a good stock to buy?

Explore More